Moderate Laryngeal Dysplasia in the Context of Classification Systems and Clinical Decision Making
The Laryngoscope · 2025-09 · 135 (9) · 3296-3305
DOI: 10.1002/lary.32200 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Laryngoscope, online erschienen am 21.04.2025. Verfasst von Flurin Mueller-Diesing und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oto-Rhino-Laryngology, Plastic, Aesthetic and Reconstructive Head and Neck Surgery, University of Würzburg, Würzburg, Germany. Hauptthemen laut MEDLINE: Laryngeal Neoplasms, Leukoplakia, Precancerous Conditions, Clinical Decision-Making. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Interdisciplinary Centre for Clinical Science (IZKF) of the University of Würzburg.
Abstract (Originalsprache)
Objectives
Determining the prognosis of vocal fold leukoplakia remains challenging. The 2017 WHO Classification of Head and Neck Tumors proposed a two‐tier grading system for classifying laryngeal precursor lesions. This resulted in the upstaging of “moderate dysplasia” to “high‐grade dysplasia.” The aim of this study was to retrospectively analyze the rates of malignant transformation in relation to the grade of dysplasia.
Methods
Totally, 392 patients who underwent at least one microlaryngoscopy with biopsy for laryngeal leukoplakia were included in this study. The rate and time to malignant transformation were analyzed according to the histopathological diagnosis and the localization of the leukoplakia.
Results
Malignant transformation rates (defined as de novo occurrence of an invasive carcinoma) were low for hyperkeratosis or parakeratosis and mild dysplasia, but comparably high for moderate dysplasia, severe dysplasia, and carcinoma in situ (CIS) (6% vs. 9% vs. 41% vs. 43% vs. 55%). The time between first biopsy and malignant transformation varied widely (0.1–10.8 years) and did not show a significant dependence on the initial histopathological diagnosis.
Conclusion
Based on the observed malignant transformation rates, the data support classifying moderate dysplasia into the “high‐grade” dysplasia group, in line with the fourth WHO classification from 2017. This implies that the clinical management of moderate dysplasia should align with that of severe dysplasia and CIS, involving histologically controlled resection. Level of Evidence 3.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oto-Rhino-Laryngology, Plastic, Aesthetic and Reconstructive Head and Neck Surgery, University of Würzburg, Würzburg, Germany.
- University of Würzburg, Institute of Pathology, Würzburg, Germany.
ORCID-Profile: Flurin Mueller-Diesing, Thomas Gehrke, Till Jasper Meyer
Förderung
- Interdisciplinary Centre for Clinical Science (IZKF) of the University of Würzburg
Zitieren
APA
Mueller-Diesing, F., Stöth, M., Ludwig, E., Rosenwald, A., Gerhard-Hartmann, E., Moratin, H., Gehrke, T., Goncalves, M., Scheich, M., Hackenberg, S., Scherzad, A., & Meyer, T. J. (2025). Moderate Laryngeal Dysplasia in the Context of Classification Systems and Clinical Decision Making. The Laryngoscope, 135(9), 3296-3305. https://doi.org/10.1002/lary.32200
Vancouver
Mueller-Diesing F, Stöth M, Ludwig E, Rosenwald A, Gerhard-Hartmann E, Moratin H, et al. Moderate Laryngeal Dysplasia in the Context of Classification Systems and Clinical Decision Making. The Laryngoscope. 2025;135(9):3296-3305. doi:10.1002/lary.32200
BibTeX
@article{MuellerDiesing2025,
author = {Mueller-Diesing, Flurin and Stöth, Manuel and Ludwig, Elena and Rosenwald, Andreas and Gerhard-Hartmann, Elena and Moratin, Helena and Gehrke, Thomas and Goncalves, Miguel and Scheich, Matthias and Hackenberg, Stephan and Scherzad, Agmal and Meyer, Till Jasper},
title = {Moderate Laryngeal Dysplasia in the Context of Classification Systems and Clinical Decision Making},
journal = {The Laryngoscope},
year = {2025},
volume = {135},
number = {9},
pages = {3296--3305},
doi = {10.1002/lary.32200}
}
EUVIMED